Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lonza to Expand ADC Manufacturing Capacity

Published: Thursday, January 10, 2013
Last Updated: Thursday, January 10, 2013
Bookmark and Share
Capacity expansion is expected to be complete in the second quarter of 2014.

Lonza has announced plans to invest CHF 14 million to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland.

Oncology therapeutics including ADCs represent one of the fastest growing segments of the pharma and biotech industry and the deployment of ADC targeted therapies has intensified in recent years.

Because cGMP manufacturing of ADCs presents unique challenges, facilities must be designed to handle both biological species and highly potent cytotoxic small molecule drugs.

Lonza has been a pioneer in the manufacturing of ADCs since its initial investment in 2006 which established manufacturing suites for both small and large scale projects, dedicated Research & Development labs, and Quality Control facilities specifically for ADCs.

Since 2010, Lonza has validated large scale manufacturing of platform technologies primarily utilized by ADC drug developers.

The expansion of the ADC facility will double the existing large-scale manufacturing capacity in Visp while allowing current operations to continue without interruption.

It is the next step in bringing challenging new technologies to one of Lonza’s main sites.

The capacity expansion, expected to be complete in the second quarter of 2014, has the potential to bring new job opportunities across all functions in Visp.

“We have witnessed significant growth in the ADC market in the past 24 months and this investment is necessary to continue to support the growing product demands from our customers” said Stefan Stoffel, Head of Lonza’s Chemical Manufacturing business unit.

Stoffel continued, “Lonza Visp will continue to offer a fully integrated end-to-end development and manufacturing solution for ADCs, including the cytotoxic small molecules used in these products and all associated analytics. In addition, Lonza can support protein development and manufacturing via our global biologics development and manufacturing sites.”

Lonza’s continued investment to increase ADC capacity and highly trained personnel allows its customers to capitalize on the unique infrastructure of the Visp site and limit their own investment in the expertise, assets, and infrastructure required to work with these highly potent biological products in a highly regulated environment.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lonza to Continue Sponsoring Horseshoe Crab Conservation Initiatives Through 2016
Lonza to continue sponsorship of horseshoe crab conservation initiatives by the Ecological Research & Development Group (ERDG).
Wednesday, June 15, 2016
Leading Industry Experts to Present at Lonza’s 2nd Global Endotoxin Testing Summit
A growing list of industry experts have signed up to join the speaker panel at Lonza’s 2nd Global Endotoxin Testing Summit from 23-25 May 2016, Annapolis, MD, and Pickering Beach, DE (USA).
Tuesday, March 01, 2016
Lonza to Build Capabilities for Drug Product Development
Company to Develop Drug Product Services for Customers by building its capabilities step-wise over the coming years.
Friday, February 05, 2016
Lonza to Build Capabilities for Drug Product Development Services
Lonza is entering the field of Drug Product Development Services for customers by building its capabilities step-wise over the coming years.
Friday, February 05, 2016
Lonza and Benitec Enter Agreement
Agreement to develop scalable AAV manufacturing process for ddRNAi therapeutics.
Friday, October 09, 2015
Lonza and CytoMate Collaboration on CytoSMART™ Technology
Agreement for global distribution of the new technology which is designed for easy, affordable live cell imaging.
Thursday, March 05, 2015
Lonza and arGEN-X Announces Commercial License Agreement
A multi-product GS Xceed™ license agreement for the production of therapeutic antibodies.
Friday, February 20, 2015
Lonza and BioWa Sign Licensing Agreement with MedImmune
MedImmune has licensed Potelligent® CHOK1SV Cell Line Technology to both Companies.
Monday, December 16, 2013
Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents
Agreement allows Hyglos to use recombinant factor C technology to produce its own endotoxin products.
Friday, March 15, 2013
Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin
Lonza will manufacture talactoferrin at its microbial facility in Kourim, Czech Republic.
Thursday, April 19, 2012
Lonza Appoints Richard Ridinger as New CEO
Board of Directors elects Mr. Ridinger at a meeting on 2 April 2012.
Thursday, April 05, 2012
Lonza Expands Singapore Bioservices
The expansion will support cell line construction, upstream and downstream process development, and a broad range of analytical services.
Monday, June 13, 2011
Lonza Selects IDBS to Optimize Bioprocess Execution & Knowledge Management
Lonza has chosen IDBS to provide an electronic data management and execution solution for mammalian cell culture process development. Lonza will deploy IDBS's Bioprocess Execution System to optimize the management of process development data and drive operational excellence.
Wednesday, January 05, 2011
Lonza Acquires Viral Vaccine and Vector Manufacturer Vivante GMP Solutions
Lonza expands its custom service platform to viral vaccines and gene therapy vectors.
Tuesday, August 31, 2010
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
Lonza provides process development services and manufacturing capacity for this product using Lonza's GS Gene Expression System™.
Wednesday, June 17, 2009
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Manufactured Stem Cells to Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Gender Determination in Forensic Investigations
This study investigated the effectiveness of lip print analysis as a tool in gender determination.
Identifying Novel Types of Forensic Markers in Degraded DNA
Scientists have tried to verify the nucleosome protection hypothesis by discovering STRs within nucleosome core regions, using whole genome sequencing.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Starving Stem Cells May Enable Scientists To Build Better Blood Vessels
Researchers from the University of Illinois at Chicago College of Medicine have uncovered how changes in metabolism of human embryonic stem cells help coax them to mature into specific cell types — and may improve their function in engineered organs or tissues.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!